716 related articles for article (PubMed ID: 26565997)
1. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
2. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
3. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
4. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Trosman SJ; Koyfman SA; Ward MC; Al-Khudari S; Nwizu T; Greskovich JF; Lamarre ED; Scharpf J; Khan MJ; Lorenz RR; Adelstein DJ; Burkey BB
JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):457-62. PubMed ID: 25742025
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of extranodal extension in human papillomavirus-associated oropharyngeal squamous cell carcinoma.
An Y; Park HS; Kelly JR; Stahl JM; Yarbrough WG; Burtness BA; Contessa JN; Decker RH; Koshy M; Husain ZA
Cancer; 2017 Jul; 123(14):2762-2772. PubMed ID: 28323338
[TBL] [Abstract][Full Text] [Related]
6. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival unique to surgically treated p16+ oropharyngeal cancer.
Haughey BH; Sinha P
Laryngoscope; 2012 Sep; 122 Suppl 2():S13-33. PubMed ID: 22926949
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
9. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study.
Chen AM; Felix C; Wang PC; Hsu S; Basehart V; Garst J; Beron P; Wong D; Rosove MH; Rao S; Melanson H; Kim E; Palmer D; Qi L; Kelly K; Steinberg ML; Kupelian PA; Daly ME
Lancet Oncol; 2017 Jun; 18(6):803-811. PubMed ID: 28434660
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma.
Malm IJ; Fan CJ; Yin LX; Li DX; Koch WM; Gourin CG; Pitman KT; Richmon JD; Westra WH; Kang H; Quon H; Eisele DW; Fakhry C
Cancer; 2017 May; 123(10):1768-1777. PubMed ID: 28055120
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of the biomarker p16 in oropharyngeal squamous cell carcinoma.
Oguejiofor KK; Hall JS; Mani N; Douglas C; Slevin NJ; Homer J; Hall G; West CM
Clin Oncol (R Coll Radiol); 2013 Nov; 25(11):630-8. PubMed ID: 23916365
[TBL] [Abstract][Full Text] [Related]
14. ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas.
Beitler JJ; Quon H; Jones CU; Salama JK; Busse PM; Cooper JS; Koyfman SA; Ridge JA; Saba NF; Siddiqui F; Smith RV; Worden F; Yao M; Yom SS;
Head Neck; 2016 Sep; 38(9):1299-309. PubMed ID: 27330003
[TBL] [Abstract][Full Text] [Related]
15. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
16. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
Lin TA; Garden AS; Elhalawani H; Elgohari B; Jethanandani A; Ng SP; Mohamed AS; Frank SJ; Glisson BS; Debnam JM; Sturgis EM; Phan J; Reddy JP; Fuller CD; Morrison WH; Skinner HD; Rosenthal DI; Gunn GB
Cancer; 2019 May; 125(9):1536-1546. PubMed ID: 30620385
[TBL] [Abstract][Full Text] [Related]
17. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas.
Ko HC; Harari PM; Sacotte RM; Chen S; Wieland AM; Yu M; Baschnagel AM; Bruce JY; Kimple RJ; Witek ME
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2341-2350. PubMed ID: 28752235
[TBL] [Abstract][Full Text] [Related]
19. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer.
Guo T; Qualliotine JR; Ha PK; Califano JA; Kim Y; Saunders JR; Blanco RG; D'Souza G; Zhang Z; Chung CH; Kiess A; Gourin CG; Koch W; Richmon JD; Agrawal N; Eisele DW; Fakhry C
Cancer; 2015 Jun; 121(12):1977-84. PubMed ID: 25782027
[TBL] [Abstract][Full Text] [Related]
20. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
